hDcp2 inhibitors represent a class of chemical compounds that have gained prominence in the field of molecular biology and RNA metabolism research. These inhibitors are designed to specifically target and modulate the activity of hDcp2, or human decapping enzyme 2, which is an essential enzyme involved in the regulation of mRNA degradation and turnover. hDcp2 plays a central role in mRNA decapping, an early step in the degradation pathway of messenger RNA molecules. This process occurs in the cytoplasm of eukaryotic cells and is crucial for the control of gene expression by ensuring the timely removal of unwanted or degraded mRNA molecules.
hDcp2 inhibitors exert their effects by interfering with the enzymatic activity of hDcp2, disrupting its ability to catalyze the removal of the protective 5' cap structure from mRNA molecules. This interference can have profound implications for mRNA stability and degradation, influencing gene expression patterns and cellular responses. Researchers employ hDcp2 inhibitors as valuable tools to investigate the specific roles of hDcp2 in RNA metabolism, gain insights into the molecular mechanisms governing mRNA degradation, and understand how the regulation of mRNA turnover contributes to cellular processes. While the specific applications and broader implications of hDcp2 inhibitors are subjects of ongoing research, their utility in elucidating the complexities of post-transcriptional gene regulation and RNA decay is of paramount importance in the field of molecular biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Interacts with DNA and inhibits RNA polymerase, potentially decreasing hDcp2 mRNA synthesis due to transcriptional inhibition. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
Specifically inhibits RNA polymerase II, potentially reducing hDcp2 mRNA transcription and subsequent protein expression. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Known to inhibit transcriptional activity by affecting RNA polymerase II, possibly leading to decreased expression of hDcp2. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Forms DNA crosslinks, inhibiting DNA replication and transcription, potentially resulting in reduced hDcp2 expression. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Inhibits DNA topoisomerase I, leading to DNA damage and potentially suppressing hDcp2 mRNA transcription. | ||||||
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $82.00 $300.00 $1082.00 | 30 | |
Inhibits DNA polymerase, potentially leading to inhibited replication and indirectly reducing hDcp2 mRNA levels. | ||||||
Ellipticine | 519-23-3 | sc-200878 sc-200878A | 10 mg 50 mg | $142.00 $558.00 | 4 | |
Intercalates with DNA and inhibits various DNA-processing enzymes, possibly resulting in decreased hDcp2 expression. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Inhibits DNA topoisomerase II, potentially leading to DNA damage and a reduction in hDcp2 mRNA levels. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Inhibits translation initiation and may affect the post-transcriptional regulation of hDcp2 mRNA, reducing its expression. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Inhibits eukaryotic initiation factor 4A, which could decrease hDcp2 mRNA translation, lowering the protein level. | ||||||